Aspect Biosystems Announces $200 Million Partnership with the Governments of Canada & BC

Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, recently announced that it has received a $72.75 million investment from the Governments of Canada and British Columbia. The investment will support a $200 million, multi-year project to advance Aspect’s unique clinical biomanufacturing capabilities, full-stack tissue therapeutic platform, and pipeline of bioprinted tissue therapeutics.

Aspect Biosystems presented at the OBIO® Investment Summit.